The DOI matches its Crossref record.
Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group
Open accessAbstract
The Multicenter Diltiazem Postinfarction Trial (MDPIT) reported no consistent diltiazem effect on new or worsened congestive heart failure (CHF) during 12-52 months' follow-up after acute myocardial infarction. This was puzzling in light of the observation that patients with findings suggesting left ventricular dysfunction (LVD) at baseline on diltiazem had more cardiac events (cardiac mortality or recurrent nonfatal infarction) than such patients on placebo. We hypothesized that diltiazem increased the frequency of late CHF as well as of cardiac events, but only in patients predisposed by LVD. Using the same characterizing variables as the primary MDPIT analysis, we found that patients with pulmonary congestion, anterolateral Q wave infarction, or reduced ejection fraction (EF) at baseline were more likely to have CHF during follow-up than those without these markers of LVD. CHF was particularly frequent in the patients with LVD who were randomized to diltiazem. Among those with a baseline EF of less than 0.40, late CHF appeared in 12% (39/326) receiving placebo and 21% (61/297) receiving diltiazem (p = 0.004). Life table analysis in patients with an EF of less than 0.40 confirmed more frequent late CHF in those taking diltiazem (p = 0.0017). In addition, the diltiazem-associated rise in the frequency of late CHF was progressively greater with increasingly severe decrements in baseline EF. This diltiazem effect was absent in patients with pulmonary congestion at baseline but an EF of 0.40 or more, suggesting a unique association between diltiazem-related late CHF and systolic LVD.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as diltiazem and verapamil can have negative inotropic effects in patients with LVEF < 40%.222,534,535”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [535]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 14
- Hossack KF, Pool PE, Steel P, Crawford MH, DeMaria AN, Cohen LS, Ports TA: Efficacy of diltiazem in angina on effort: A multicenter trial. Am J Cardiol 1982;49:567-572
- Strauss WE, McIntyre KM, Parisi AF, Shapiro W: Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: Report of a cooperative clinical trial. Am J Cardiol 1982;49:560-566
- Pepine CJ, Feldman RL, Hill JA, Conti CR, Mehta J, Hill C, Scott E: Clinical outcome after treatment of rest angina with calcium blockers: Comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil. Am Heart J 1983;106:1341-1347
- Boden WE, Bough EW, Reichman MJ, Rich VB, Young PM, Korr KS, Schulman RS: Beneficial effects of high-dose dil- tiazem in patients with persistent effort angina on p-blockers and nitrates: A randomized, double-blind, placebo-controlled cross-over study. Circulation 1985;71:1197-1205
- Porter CB, Walsh RA, Badke FR, O'Rourke RA: Differential effects of diltiazem and nitroprusside on left ventricular function in experimental chronic volume overload. Circulation 1983;68:685-692
- Murakami T, Hess OM, Krayenbuehl HP: Left ventricular function before and after diltiazem in patients with coronary artery disease. JAm Coll Cardiol 1985;5:723-730
- The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392
- Greenberg H, Gillespie J, Dwyer EM Jr, the Multicenter Post-Infarction Research Group: A new electrocardiographic classification for post-myocardial infarction clinical trials. Am J Cardiol 1987;59:1057-1063
- Kaplan EL, Meier P: Nonparametric estimation from incom- plete observations. JAm Stat Assoc 1958;53:457-481
- Marcus FI, Friday K, McCans J, Moon T, Hahn E, Cobb L, Edwards J, Kuller L: Age-related prognosis after acute myo- cardial infarction (the Multicenter Diltiazem Post-Infarction Trial). Am J Cardiol 1990;65:559-566
- Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510
- Packer M, Gottlieb SS, Kessler PD: Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. The basis of a new physiologic approach to control of arrhythmia. Am J Med 1986;80:23-29
- Packer M, Meller J, Medina N, Yushak M, Smith H, Holt J, Guererro J, Todd GD, McAllister RG Jr, Gorlin R: Hemody- namic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982;65:660-668
- Joshi PI, Dalal JJ, Ruttlet MSJ, Sheridan DJ, Henderson AH: Nifedipine and left ventricular function in beta-blocked patients. Br Heart J 1981;45:457-459
Cited by
Sorted by citations
Items 301–400 of 525
The ever expanding spectrum of ischemic left ventricular dysfunction
Opie, L. H. (1994) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877313 · Cited by 9
Innovations in the Pharmacologic Management of Heart Failure
Michael, K. A., & Parnell, K. J. (1998) · AACN Clinical Issues Advanced Practice in Acute & Critical Care · doi:10.1097/00044067-199805000-00003 · Cited by 9
Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons
Aronow, W. S. (2005) · The Journals of Gerontology Series A · doi:10.1093/gerona/60.12.1597 · Cited by 9
Masui, M., Funakawa, S., Uno, O., et al. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199610000-00008 · Cited by 9
Heart Failure–Complicating Acute Myocardial Infarction
Aronow, W. S. (2007) · Heart Failure Clinics · doi:10.1016/j.hfc.2007.07.010 · Cited by 9
Fowler, N. O. (1993) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-3516-4_13 · Cited by 9
Maximizing benefits of therapies in acute myocardial infarction
Feuvre, C. L., Yusuf, S., Flather, M. D., & Farkouh, M. E. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90121-r · Cited by 9
Angiotensin-converting enzyme inhibitors and calcium antagonists after acute myocardial infarction
Poole-Wilson, P. A. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80441-x · Cited by 9
Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart
Katz, A. M. (1995) · Trends in Cardiovascular Medicine · doi:10.1016/1050-1738(94)00030-y · Cited by 9
Optimising heart failure pharmacotherapy: the ideal combination
Cleland, J. G. F., & Dutka, D. P. (1994) · Heart · doi:10.1136/hrt.72.2_suppl.s73 · Cited by 9
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Rimskaya, E. M., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-2-6-76 · Cited by 8
Triska, J., Tamargo, J. L., Bozkurt, B., Elkayam, U., Taylor, A. A., & Birnbaum, Y. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07334-y · Cited by 8
“To begin, the findings of the MDPIT [17, 48] and DAVIT trials [5–14, 17, 32, 48–52] appear to be at odds with one another.”
Dong, Y., Alcusky, M. J., Maio, V., Liu, J., Liu, M., Wu, L., Chang, C., Lai, M., & Gagne, J. J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012997 · Cited by 8
Managing the elderly patient with hypertension: current strategies, challenges, and considerations
Aronow, W. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1732206 · Cited by 7
Takeuchi, K., Omura, T., Yoshiyama, M., et al. (1999) · Heart and Vessels · doi:10.1007/bf02482294 · Cited by 8
Safety of calcium antagonists in patients with congestive heart failure
Katz, S. D. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80039-2 · Cited by 8
Calcium Antagonist Use in Congestive Heart Failure: Still a Bridge Too Far?
Piepho, R. W. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04087.x · Cited by 8
Smith, R. F., Germanson, T., Judd, D., et al. (2000) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(00)90011-3 · Cited by 8
Shimoyama, H., Sabbah, H. N., Tanimura, M., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37438-5 · Cited by 8
“…a spectrum of cardiac diseases including unstable angina, myocardial infarction and HF showed either no clinical improvement or an increase in cardiovascular morbidity and mortality (Goldstein et al., 1991; Muller et al., 1984; The Multicenter Diltiazem Postinfarction Trial Research Group, 1988).”
Sugiyama, A., & Hashimoto, K. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199901000-00011 · Cited by 8
Current concepts in secondary prevention after acute myocardial infarction
Mehta, R. H., Bossone, E., & Eagle, K. A. (2000) · Herz · doi:10.1007/bf03044123 · Cited by 8
Amlodipine in Chronic Heart Failure
Bobbio, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361413 · Cited by 8
Tsai, E. J., Wilkoff, B. L., Mitchell, J. E., Peterson, P. N., Riegel, B. J., Sam, F., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., et al. (2013) · Cited by 7
Atrial Fibrillation in Heart Failure—Diagnostic, Therapeutic, and Prognostic Relevance
Stegmann, C., & Hindricks, G. (2019) · Current Heart Failure Reports · doi:10.1007/s11897-019-00430-5 · Cited by 7
Hypocalcemic cardiomyopathy: A case report
Wen, Y., & Luo, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.999550 · Cited by 7
Gene therapies for arrhythmias in heart failure
Akar, F. G., & Hajjar, R. J. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1485-3 · Cited by 7
“Unfortunately, available pharmacological agents that shorten APD, such as calcium channel blockers, are not ideal in certain situations because of their confounding effects on contraction in a patient population that often requires inotropic support [24].”
Grubb, A. F., & Mentz, R. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1732210 · Cited by 10
“These drugs are routinely avoided in HF patients (and contraindicated in HFrEF) multiple clinical trials (Table 2) have demonstrated no clinical benefit [61,62] or worse outcomes [63,64].”
BackgroundAlvarez, P. A., Gao, Y., Girotra, S. R., Mentias, A. G., Briasoulis, Α., & Vaughan‐Sarrazin, M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12752 · Cited by 7
“In addition, although it was not a pre-specified endpoint, patients treated with diltiazem who had pulmonary congestion at baseline and reduced ejection fraction (EF) were more likely to have CHF during follow-up than those treated with placebo.(32) The evidence of harm was not reproduced in a small trial of patients…”
Acute Decompensated Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
Fukata, M. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.12.007 · Cited by 6
The clinical significance of neurohormonal activation
Pool, P. E. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80037-9 · Cited by 7
O’Connor, C. M., Radensky, P. W., Unger, A. N., et al. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80027-2 · Cited by 7
Čatipović-Veselica, K., Ilakovac, V., Durjanček, J., et al. (1996) · Psychological Reports · doi:10.2466/pr0.1996.79.1.259 · Cited by 7
The Management of Co-Morbidities in Patients with Heart Failure – Angina and Coronary Disease
Spoletini, I., & Seferovic, P. M. (2017) · International Cardiovascular Forum Journal · doi:10.17987/icfj.v10i0.451 · Cited by 6
Wahed, M. I. I., Watanabe, K., Ma, M., et al. (2004) · Pharmacology · doi:10.1159/000078629 · Cited by 6
Girouard, C., Grégoire, J., Poirier, P., et al. (2017) · Medicine · doi:10.1097/md.0000000000006239 · Cited by 6
“patients with HF come from studies in patients who had a myocardial infarction.([9,10]) Previous studies on the effects of potentially inappropriate drugs in patients with HF, took place either when the b-blockers and ACEI were not yet standard therapy for HF, with respect to exposure to nifedipine,([11]) or as a seco…”
BackgroundSethi, N. J., Safi, S., Feinberg, J. B., Nielsen, E. E., Gluud, C. N., & Jakobsen, J. C. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0470-2 · Cited by 7
Olivari, M.-T. P. (2000) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(99)00106-0 · Cited by 6
Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly
Aronow, W. S. (2007) · Heart Failure Clinics · doi:10.1016/j.hfc.2007.07.007 · Cited by 6
Current Management of Pulmonary Hypertension
Dincer, H. E., & Presberg, K. W. (2004) · Clinical Pulmonary Medicine · doi:10.1097/01.cpm.0000107641.66465.1e · Cited by 6
Secondary Prevention with Calcium Antagonists after Acute Myocardial Infarction
Hansen, J. F. (1992) · Drugs · doi:10.2165/00003495-199200441-00007 · Cited by 6
Evolving therapeutic concepts and imaging in ischemic cardiomyopathy
Lahiri, A., & Senior, R. (1998) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(98)90114-3 · Cited by 6
Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction
Boehmer, A. A., Ehrlich, J. R., & Nattel, S. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.09.014 · Cited by 10
Self-citationAbdin, A., Bauersachs, J., Abdelhamid, M., Aktaa, S., Ghorani, H. A., Bayés‐Genís, A., Biegus, J., Böhm, M., Butler, J., Girerd, N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70087 · Cited by 7
Implications of the New National Guidelines for Hypertension
Aronow, W. S., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000187 · Cited by 5
“Nondihydropyridine calcium-channel blockers are contraindicated in persons who have heart failure and a decreased left ventricular ejection fraction.(31,45,70,71) Persons with hypertension and heart failure with a preserved left ventricular ejection fraction should have their volume overload treated with diuretics, th…”
BackgroundUse of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study
Diemberger, I., Spadotto, A., Massaro, G., Amadori, M., Damaschin, L., Martignani, C., Ziacchi, M., Biffi, M., Galiè, N., & Boriani, G. (2022) · Biology · doi:10.3390/biology12010022 · Cited by 5
“Most of the patients (55%) were receiving concomitant betablockers [29].”
BackgroundPREOPERATIVE ASSESSMENT OF PATIENTS WITH CARDIAC DISEASE UNDERGOING NONCARDIAC SURGERY
Kurki, T. S. O. (1997) · Anesthesiology Clinics of North America · doi:10.1016/s0889-8537(05)70313-8 · Cited by 5
Recent advances in management of atrial fibrillation in patients with heart failure
Shantsila, E., & Lip, G. Y. H. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32835bd465 · Cited by 5
Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists
Martirosyan, H. A., Brass, E. P., Mehrotra, R., & Adler, S. G. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.04.036 · Cited by 5
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Cited by 5
Aronow, W. S. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.01.26 · Cited by 6
Five-Year Outcomes of Heart Failure with Preserved Ejection Fraction
Macía-Rodríguez, C., Páez-Guillán, E., Alende-Castro, V., García-Villafranca, A., Mateo‐Mosquera, L., Martínez-Braña, L., García, M., & Lado, F. L. L. (2020) · The Open Cardiovascular Medicine Journal · doi:10.2174/18741924020140100018 · Cited by 5
Ray, L., Geier, C., & DeWitt, K. M. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad108 · Cited by 6
Nicklas, J. M., Bleske, B. E., Harrison, R. V., Hogikyan, R. V., Kwok, Y. S., & Chavey, W. E. (2013) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.010 · Cited by 5
Reassessing the use of vasodilators in heart failure
Cole, R. T., Gheorghiade, M., Georgiopoulou, V. V., Gupta, D. M., Marti, C. N., Kalogeropoulos, A. P., & Butler, J. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.108 · Cited by 4
The Use of Calcium Channel Blockers in Heart Failure
Vider, E., & Zada, I. (2018) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2018.07.009 · Cited by 5
Aronow, W. S. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.07.006 · Cited by 4
Current and novel pharmacologic approaches in advanced heart failure
O’Connor, C. M., Gattis, W. A., & Swedberg, K. B. (1999) · Heart & Lung · doi:10.1016/s0147-9563(99)70069-5 · Cited by 5
Aronow, W. S. (2000) · Coronary Artery Disease · doi:10.1097/00019501-200006000-00006 · Cited by 5
Heart Failure Complicating Acute Myocardial Infarction
Aronow, W. S. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.02.007 · Cited by 5
Maki, N., Yoshiyama, M., Omura, T., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1013711619856 · Cited by 5
Opie, L. H. (1991) · Cardiovascular Drugs and Therapy · doi:10.1007/bf03029739 · Cited by 5
Heart failure in 2001: a prophesy revisited
Katz, A. M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01557-0 · Cited by 5
ACE inhibitors and calcium antagonists in the treatment of congestive heart failure
Hansen, J. F. (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877862 · Cited by 5
Evaluation of Anti-Ischemic Therapy in Coronary Artery Disease: A Review
Marwan, S. M. (2012) · InTech eBooks · doi:10.5772/30038 · Cited by 4
“Use of non-DPHs after complex MIs should be avoided because of the possibility of HF as well (Packer et al., 1996; Goldstein et al., 1991).”
Association between coronary angiograms and cardiac events — a prospective 3-year follow-up
Jost, S., Nikutta, P., Deckers, J. W., Wiese, B., & the INTACT-investigators (1998) · International Journal of Cardiology · doi:10.1016/s0167-5273(98)00138-7 · Cited by 4
Beta Blockers and Calcium Channel Blockers
Neagoe, A., Rexhaj, E., Grossman, E., & Messerli, F. H. (2019) · Contemporary cardiology · doi:10.1007/978-3-030-19131-3_6 · Cited by 4
Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults
Aronow, W. S. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.02.004 · Cited by 4
The secondary prevention of myocardial infarction
Michaels, A. D. (1999) · Current Problems in Cardiology · doi:10.1016/s0146-2806(99)90010-5 · Cited by 5
Chronic Angina Pectoris: Inadequacies of Current Therapy
Parker, J. O. (2004) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2004.02519.x · Cited by 4
Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation
Wongcharoen, W., & Chen, S. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.7.3.311 · Cited by 4
CURRENT TRENDS IN THE MANAGEMENT OF HEART FAILURE
Wald, T., Gaulden, L. H., Beyler, M., Whellan, D. J., & Bowers, M. (2000) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02643-3 · Cited by 4
Neurohormones in patients with ischemic left ventricular dysfunction
Pouleur, H. G., Benedict, C. R., & Rousseau, M. F. (1994) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877315 · Cited by 4
Treatment of the Elderly Post‐Myocardial Infarction Patient
Aronow, W. S. (2001) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2001.00647.x · Cited by 4
Jespersen, C. M. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00306-2 · Cited by 4
T-channel—selective calcium channel blockade: a review of published data and therapeutic potential
van der Vring, J. A., Cleophas, T. J., van der Wall, E. E., et al. (1998) · Current Therapeutic Research · doi:10.1016/s0011-393x(98)85101-1 · Cited by 4
Secondary Prevention With Calcium Antagonists After a Myocardial Infarction
Hansen, J. F. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410190123015 · Cited by 4
Tanguay, M., Jasmin, G., Blaise, G. A., et al. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199608000-00008 · Cited by 4
Effective management of complex heart failure
Kosseim, L. M., Pifer, E. A., & Zimmer, R. (1999) · Postgraduate Medicine · doi:10.1080/00325481.1999.11444919 · Cited by 4
Current Approaches to the Treatment of Hypertension in Older Persons
Aronow, W. S. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2517 · Cited by 3
Loffreda, A., Matera, M. G., Vacca, C., et al. (1999) · Current Medical Research and Opinion · doi:10.1185/03007999909115174 · Cited by 3
Bae, S., Kim, W. K., You, S. C., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1305824 · Cited by 3
Polypill and Combination Therapy: Blood Pressure and Cardiovascular Risk Reduction
Park, J., Yang, C.-W., Huan, Y., & Aggarwal, S. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-02000-7 · Cited by 3
Integration of electrophysiological and mechanical biomarkers in cardiac risk assessment models
Priego, L., Mora, M. T., Llopis‐Lorente, J., Finsberg, H. N. T., Daversin, C., Herck, I. V., Wall, S., Arevalo, H., Saiz, F. J., & Trénor, B. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108896 · Cited by 3
Treatment After Myocardial Infarction
Aronow, W. S. (2007) · Comprehensive Therapy · doi:10.1007/s12019-007-0002-4 · Cited by 3
Heart-rate slowing drugs in the treatment of myocardial infarction survivors
Vítovec, J., & Špinar, J. (2009) · Cor et Vasa · doi:10.33678/cor.2009.026 · Cited by 3
The Care of Patients With Atrial Fibrillation and Heart Failure
Abbasi, M. H., Maan, A., & Heist, E. K. (2020) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000235 · Cited by 3
Heart-Failure–Complicating Acute Myocardial Infarction
Aronow, W. S. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2006.08.005 · Cited by 3
The treatment of heart failure—what next?
Davies, R. L., & Sheridan, D. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb04181.x · Cited by 3
Are calcium antagonists safe in hypertension?
Lip, G. Y. H., & Beevers, D. G. (1996) · Postgraduate Medical Journal · doi:10.1136/pgmj.72.846.193 · Cited by 3
[Prevention and treatment of hypertension and coronary heart disease].
Mendoza-González, C., Rosas, M., Lomelí, C., Lorenzo, J. A., Méndez, A., Martínez-Réding, J., Martínez‐Sánchez, C., Pastelı́n, G., Férez-Santander, S. M., & Attié, F. (2008) · PubMed · Cited by 3
Calcium antagonists: past, present and future - a personal view
Nayler, W. G. (1999) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 3
Massie, B. M., & Amidon, T. M. (1994) · Congestive Heart Failure · doi:10.1007/978-1-4613-8315-4_23 · Cited by 3
HEART FAILURE COMPLICATING ACUTE MYOCARDIAL INFARCTION
Aronow, W. S. (2000) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(05)70027-6 · Cited by 3
Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly
Aronow, W. S. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2006.08.004 · Cited by 3
Molekulare Grundlagen der Herzinsuffizienz
Thomas Eschenhagen, A., & Weil, J. (1998) · Springer eBooks · doi:10.1007/978-3-642-80360-4_5 · Cited by 3
Management of the Older Patient After Myocardial Infarction
Aronow, W. S. (2008) · Fundamental and clinical cardiology · doi:10.3109/9781420061710.012 · Cited by 2
Aurora, L., & McCord, J. (2017) · Contemporary cardiology · doi:10.1007/978-3-319-44006-4_20 · Cited by 2
2018 Korean Heart Rhythm Society Guidelines for The Rate Control of Atrial Fibrillation
Lim, W., Choi, E., Joung, B., & Choi, K. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.133 · Cited by 2
“박출률 저하 심부전의 경우 베타차단제와 디곡신 또는 이 들의 병용 사용을 추천하며, 딜티아젬이나 베라파밀은 심실 수축력을 저하시킬 수 있어 사용에 주의해야 한다[10].”
Foster, E. M., Coons, J. C., Puccio, E. A., et al. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241243071 · Cited by 2
Frick, W. H., Zhang, Z., Rogers, L., Rojulpote, C., & Lin, C.-J. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102669 · Cited by 2
Metadata
- Authors
- Goldstein, R. E., Boccuzzi, S. J., Cruess, D., & Nattel, S.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Venue
- Circulation
- Published
- 1991-01
- Volume
- 83
- Issue
- 1
- Pages
- 52-60
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2090674352
- Cited by
- 521
- References
- 0
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 16 · 2022: 16 · 2021: 7 · 2020: 24 · 2019: 13 · 2018: 15 · 2017: 17 · 2016: 15 · 2015: 17 · 2014: 4 · 2013: 16 · 2012: 11
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Henry M. Jackson Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- diltiazem, congestive heart failure, myocardial infarction, left ventricular dysfunction, ejection fraction, calcium channel blockers, pulmonary congestion, adverse drug reactions
- MeSH terms
- Diltiazem, Double-Blind Method, Follow-Up Studies, Heart Failure, Humans, Myocardial Infarction, Stroke Volume, Life Tables, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
